Is Summit Therapeutics Stock a Buy?
Summit Therapeutics' (NASDAQ: SMMT) shares are up by more than 1,060% in the last 12 months, thanks to the market's exuberant reaction to the latest sets of clinical trial data produced by the company and its main collaborator. Now the question is whether Summit can continue wowing investors as its candidates approach their shot at commercialization.
But you might look at its pipeline and conclude that the biotech is a one-trick pony, as its lack of diversification is acute. So is this stock's value a bubble that's just waiting for a setback before it pops and crashes, or is it capable of bringing home the bread?
At the moment, Summit is running a pair of phase 3 clinical trials to see whether its biologic called ivonescimab is useful to treat two subsets of non-small cell lung cancer (NSCLC).
Source Fool.com
